Clinical Trial Finder
Blaze a trail to better treatments and a cure for cystic fibrosis.
Due to COVID-19, restrictions regarding enrollment may be in place. Please contact study sites directly to learn about their screening and enrollment status.
As a clinical trial volunteer, you are paving the way for new treatments. Search or filter for trials that may be right for you, or learn more about what it means to be a trailblazer.
Showing 1-6 of 184 studies
As a clinical trial volunteer, you are paving the way for new treatments. Search for trials that may be right for you using the filter on the left, or learn more about what it means to be a trailblazer.
Showing 1-6 of 184 studies
-
Restore CFTR FunctionEnrolling
RESTORE-CF: Phase 1/2 study of MRT5005 drug in adults with cystic fibrosis (Parts A, B and B Expansion) , protocol number Translate Bio MRT5005-101This study is taking place at multiple care centers across the U.S. It will look at the safety and tolerability of different doses of the nebulized drug MRT5005 in adults with CF.
-
Age:
18 Years and Older
-
Mutation(s):
Mutation Requirement
-
FEV1% Predicted:
50 to 90%
-
Number of Visits:
21
-
Length of Participation:
1 years
-
-
Anti-InflammatoryEnrolling
Phase 2 study of LAU-7b in adults with CF (APPLAUD) , protocol number Laurent LAU-14-01This study is taking place at multiple care centers across the U.S. It will look at the safety and effectiveness of the anti-inflammatory drug LAU-7b and will use a placebo control.
-
Age:
18 Years and Older
-
Mutation(s):
No Mutation Requirement
-
FEV1% Predicted:
40 to 100%
-
Number of Visits:
6
-
Length of Participation:
189 days
-
-
Anti-InfectiveEnrolling
ABATE: Study to evaluate IV gallium in adults with cystic fibrosis who have nontuberculous mycobacteria (NTM) , protocol number ABATE-IP-18This study is taking place at multiple care centers across the U.S. It will look at the safety and tolerability of IV gallium, a drug intended to treat infections in the lung.
-
Age:
18 Years and Older
-
Mutation(s):
No Mutation Requirement
-
FEV1% Predicted:
25% or greater
-
Number of Visits:
8
-
Length of Participation:
20 weeks
-
-
Nutritional-GIEnrolling
OPTION 2: Study of AzurRX MS1819 in enteric capsules in adults with cystic fibrosis and exocrine pancreatic insufficiency , protocol number AzurRX AZ-CF2002This study will look at the safety and effectiveness of the drug MS1819 in enteric capsules as a pancreatic enzyme replacement therapy (PERT).
-
Age:
18 Years and Older
-
Mutation(s):
No Mutation Requirement
-
FEV1% Predicted:
30% or greater
-
Number of Visits:
10
-
Length of Participation:
8 weeks
-
-
ObservationalEnrolling
Study to evaluate the effects of CFTR modulators in infants and young children (BEGIN Part B) , protocol number BEGIN-OB-19 Part BThis two-part observational study will look at the effects of CFTR modulators on growth in young children with CF. These drugs are intended to help CFTR protein function closer to normal.
-
Age:
Less than 6 Years
-
Mutation(s):
Mutation Requirement
-
FEV1% Predicted:
No FEV1 Limit
-
Number of Visits:
6
-
Length of Participation:
2 years
-
-
OtherEnrolling
Study of SPI-1005 in people with CF ages 18 and older , protocol number Sound Pharma SPI-3005-501.2This study will test the safety and tolerability of SPI-1005, a drug intended to prevent and treat hearing loss caused by aminoglycosides.
-
Age:
18 Years and Older
-
Mutation(s):
No Mutation Requirement
-
FEV1% Predicted:
40% or greater
-
Number of Visits:
6
-
Length of Participation:
49 days
-
Showing 1-6 of 184 studies
Studies in this tool are multi-center studies facilitated by the Cystic Fibrosis Therapeutics Development Network. For a complete list of cystic fibrosis related studies, visit www.clinicaltrials.gov.
Related Topics
-
Questions to Ask When Considering a Specific Trial
Clinical trials that test potential drugs and therapies in people with cystic fibrosis are a major part of CF research. They take place at Cystic Fibrosis Foundation-accredited care centers all over the United States and enroll people with CF of all ages.
-
Patient Safety Is a Priority
Nothing is more important than patient safety in developing new treatments for cystic fibrosis. The U.S. government requires that all clinical trials are supervised for safety, and the Cystic Fibrosis Foundation adds additional measures to protect study volunteers.
-
Trikafta™
The following is a collection of information and news about Trikafta™, the triple-combination modulator therapy that was approved by the U.S. Food and Drug Administration on Oct. 21, 2019.
Sign up for clinical trial alerts
Get email updates about clinical trials that matter to you.
Check the Drug Development Pipeline
We’re attacking CF from every angle. Learn about the status of CF drugs in development.
Learn More